NEW YORK, December 17, 2014 /PRNewswire/ --
Moments ago, Realtime Equities released new analyst updates
concerning several important developing situations including Encana
(NYSE: ECA), Unisys (NYSE: UIS), Salix (NASDAQ: SLXP), Cerus
(NASDAQ: CERS), and Eli Lilly (NYSE: LLY). Realtime Equities is the
leader in realtime news, commentary and analysis - proudly
employing registered CFA® research staff and rigorous compliance
procedures. The full research reports are being made available to
the public for informational purposes only.
To access our full PDF reports on a complementary basis,
please visit the links at the bottom.
--
Analyst Update: Spending Plan
Updates,Appointments,Inventory
Targets, andFDA Approvals
Reviewed by: Rohit Tuli,
CFA®
The US stock market on Tuesday witnessed its most volatile
session since mid-October. Markets ended on a negative note amid
slumping oil prices and growing chaos in Russia, represented by a massive decline of
the ruble. The NASDAQ Composite edged 1.24% lower, the Dow Jones
Industrial Average declined 0.65% and the S&P 500 fell 0.85%. A
global emerging -market selloff which started on Monday, further
pressurized Asia and the Asian
stock market on Tuesday, which ended the day in red. On the other
hand, the European Markets on December 16,
2014 closed on a positive note led by a surge in energy
shares. Further, positive data from a German analyst, an
investor sentiment ZEW survey and a fund manager survey from Bank
of America Merrill Lynch helped sustain the investor sentiment in
the European Market.
Undeterred by the continued slump in crude oil prices, the
Calgary, Alberta-based Encana
Corporation (Encana) announced 2015 capital program of between
$2.7 billion and $2.9 billion, which
is above the Company's planned 2014 spending target. Encana said
that 80% of its spending in 2015 will be focused on four of its
highest margin growth plays; the Montney, Duvernay, Eagle Ford and Permian. Click on the
report below to find out about shareholders' reaction to Encana's
2015 spending plan.
Unisys Corporation (Unisys) has named Peter A. Altabef as its new President and CEO.
In addition, the Company announced that Paul E. Weaver, currently interim Chairman of
the Unisys board, will become Chairman. The changes come into
effect from January 1, 2015. Click on
the report below to know more about Unisys' new chief.
Salix Pharmaceuticals, Ltd. (Salix) announced plans to bring
down the wholesaler inventory levels to the Company's target of
approximately three months by the end of 2015 - one year earlier
than previously announced. Salix said that the move to accelerate
reduction in inventory levels reflects views expressed by its
largest shareholders. Click on the link below to know more about
Salix's inventory reduction plans and updates on earnings
outlook.
Cerus Corporation (Cerus) announced that the U.S. Food and Drug
Administration (FDA) has approved the INTERCEPT Blood System for
plasma that reduces the risk of transfusion-transmitted infection
(TTI) when treating patients requiring therapeutic plasma
transfusion. Shares of Cerus rallied over 22% in after-hours
trading session on Tuesday. Click on the link below to find out how
Cerus' new system scores better over existing tests.
Eli Lilly and Co. (Eli Lilly) announced that the U.S. Food and
Drug Administration (FDA) has approved use of the Company's CYRAMZA
(ramucirumab) drug in combination with docetaxel, for the treatment
of patients with metastatic non-small cell lung cancer (NSCLC) with
disease progression on or after platinum-based chemotherapy. This
marks the third FDA approval for CYRAMZA. Find out more about the
Eli Lilly's CYRAMZA by clicking on the report below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the
following links into your browser):
ECA Research Report: (
http://get.realtimeequities.com/pdf/?c=Encana&d=17-Dec-2014&s=ECA
),
UIS Research Report: (
http://get.realtimeequities.com/pdf/?c=Unisys&d=17-Dec-2014&s=UIS
),
SLXP Research Report: (
http://get.realtimeequities.com/pdf/?c=Salix&d=17-Dec-2014&s=SLXP
),
CERS Research Report: (
http://get.realtimeequities.com/pdf/?c=Cerus&d=17-Dec-2014&s=CERS
),
LLY Research Report: (
http://get.realtimeequities.com/pdf/?c=Eli%20Lilly&d=17-Dec-2014&s=LLY
). ============
--
About Realtime Equities
Tired of missing trades? In a world where information travels at
the speed of light, you can't afford to be out of touch. Get an
actionable source of information. Find the best opportunities
available in real-time. Don't waste time trying to chase the news,
get ahead of it with Realtime Equities. We find information as it
happens and send it out to our subscribers in our e-alerts. Our
focus is to find companies positioned to see upward momentum,
delivering alerts to your inbox as the event unfolds in realtime.
Join us in our battle to beat the markets, you'll be happy you
did.
We are proud to serve professional traders, financial advisors,
hedge funds and experience individual investors including some of
the top firms on wall-street today. For more information about our
service offerings and subscriptions, please visit our website or
reach out to our sales staff. Advanced subscription packages are
available to qualifying institutional clients and accredited
investors, please speak with your account manager to learn more
about these custom opportunities.
If you enjoyed today's content, subscribe to our live updates
here: ( http://get.realtimeequities.com/updates )
--
Editor Note: This is not company news. We are an
independent source and our views do not reflect the companies
mentioned.
Compliance Procedure: Content is researched, written and
reviewed on a best-effort basis. This document, article or report
is prepared and authored by Realtime Equities, represented by
Rohit Tuli, CFA®. An outsourced
research services provider has only reviewed the information
provided by Realtime Equities in this article or report according
to the procedures outlined by Realtime Equities. Realtime Equities
is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or
reports, as the case may be.
Further Resources: For more information about this
release including editorial notes, compliance procedures and legal
disclosures, please visit:
http://www.realtimeequities.com/editors
Contact Information: If you need to reach out to us about
this release, please do so at:
Compliance Department
Toll Free: 1-800-632-0568
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE RealtimeEquities.com